healthcare

Gene Security Network

Why Dear Abby loves this company (and you should, too)

By John Steuart / September 12, 2011 / 0 Comments

Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If […]

Read More
MDWC2011

Sam Colella of Versant Ventures, Risa Stack of Kleiner Perkins and Alex de Winter of Mohr Davidow join me for the Molecular Diagnostics World Congress Event on September 29 at 5:15pm

By John Steuart / August 29, 2011 / 0 Comments

Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment. These challenges include the cost-efficient development of technology that is truly disruptive yet cost-competitive. Panelists will discuss how to best determine […]

Read More

Molecular Diagnostics World Congress, Venture Capitalists’ Best Practices on Commercializing Innovation

By John Steuart / July 22, 2011 / 0 Comments

I will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center. Here’s the panel topic summary, hope to see you there. Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get […]

Read More

Moving Quickly from an Idea to a Product

By Brad Webb / July 6, 2011 / 0 Comments

July 1, 2011  source: Genetic Engineering & Biotechnology News by Brad Webb Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. […]

Read More

Claremont Creek Ventures Sees An Uptick In Corporate Venture Capital: Interest Leverages Growth For Portfolio Companies

By Nat Goldhaber / July 6, 2011 / 0 Comments

I was chatting recently with Venture Capital Journal’s Mark Boslet about a story concerning corporate venture capital investing and realized that Claremont Creek Ventures is among those VC firms witnessing first-hand heightened interest among corporations investing in venture-backed startups. We’re seeing activity, in particular, in healthcare and in clean technology, and it’s a good thing. […]

Read More

Claremont Creek Ventures portfolio company AssureRx featured in WSJ article

By Claremont Creek Alerts / May 13, 2011 / 0 Comments

May 11, 2011  source: Wall Street Journal Health Blog Public Education and Gene Testing to Improve Medication Adherence There are tons of reasons why people don’t take the medications they’ve been prescribed, including side effects, cost and complicated drug regimens. A couple of different approaches to improving adherence are in the news today. The first […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives